FDA Clearance Tracker · P210036-S007
PerClot® Polysaccharide Hemostatic System
Last checked: Nov 20, 2026Latest source record: Jun 8, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Jun 8, 2026
Approved
Time to decision
167 days
Received Dec 23, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P210036-S007
- Device name
- PerClot® Polysaccharide Hemostatic System
- Applicant
- Baxter Healthcare Corporation
- Applicant location
- Round Lake, IL
- Received
- Dec 23, 2025
- Decided
- Jun 8, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P210036
Device type
- Device class
- Class III
- Regulation
- 21 CFR 878.4490
- Specialty
- General & Plastic SurgeryWound Care
FDA's approval statement
As written in FDA's record.
Approval for the transfer of production of the PerClot Absorbable Hemostatic Powder to an alternate manufacturing site, Beijing Huan Qiu Li Kang Biotech Co., Ltd., (HQLK) in Beijing, China.
Source documents
Other decisions for Baxter Healthcare Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K251745 · Decided Dec 16, 2025 · 193 days after receipt
Device type: Blood Pressure Cuff (DXQ) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.